Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

NCT05524883 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Duchenne Muscular Dystrophy (DMD)

Interventions

DRUG: DYNE-251
DRUG: Placebo

Sponsor

Dyne Therapeutics